Literature DB >> 3877182

Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations.

G Bissette, G P Reynolds, C D Kilts, E Widerlöv, C B Nemeroff.   

Abstract

The concentration of corticotropin-releasing factor-like immunoreactivity (CRF-LI) in the human central nervous system was measured by radioimmunoassay in postmortem tissue of control patients and in those with histologically confirmed senile dementia of the Alzheimer type (SDAT). In the controls, CRF-LI was found in high concentrations in the hypothalamus and frontal cortex (Brodmann's area 10), in moderate concentrations in amygdala, substantia innominata, temporal and parietal cortex (Brodmann's areas 38 and 7), and the caudate nucleus, and in low concentrations in posterior hippocampus and nucleus accumbens. A marked reduction in the concentration of CRF-LI was observed in the frontal and temporal cortex (approximately 50%) as well as in the caudate nucleus (approximately 70%) in the SDAT group. The present findings suggest that neurons containing corticotropin-releasing factor are pathologically altered in SDAT, in addition to the previously described cholinergic and somatostatinergic neuronal degeneration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3877182

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  17 in total

1.  Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer's disease.

Authors:  Jennifer Horgan; Jose Javier Miguel-Hidalgo; Martha Thrasher; Garth Bissette
Journal:  J Alzheimers Dis       Date:  2007-09       Impact factor: 4.472

Review 2.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

3.  Infantile spasms: hypothesis-driven therapy and pilot human infant experiments using corticotropin-releasing hormone receptor antagonists.

Authors:  T Z Baram; W G Mitchell; K Brunson; E Haden
Journal:  Dev Neurosci       Date:  1999-11       Impact factor: 2.984

4.  Corticotropin-releasing hormone activates ERK1/2 MAPK in specific brain areas.

Authors:  Damián Refojo; Carlos Echenique; Marianne B Müller; Johannes M H M Reul; Jan M Deussing; Wolfgang Wurst; Inge Sillaber; Marcelo Paez-Pereda; Florian Holsboer; Eduardo Arzt
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-15       Impact factor: 11.205

Review 5.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

6.  An anxiolytic role for CRF receptor type 1 in the globus pallidus.

Authors:  Yehezkel Sztainberg; Yael Kuperman; Nicholas Justice; Alon Chen
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

Review 7.  Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release.

Authors:  R Quirion
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

8.  Involvement of dopaminergic processes in the striatum during the effects of corticoliberin on the behavior of active and passive rats.

Authors:  V G Shalyapina; V V Rakitskaya; G G Rodionov
Journal:  Neurosci Behav Physiol       Date:  2003-07

Review 9.  Physiological and neurochemical aspects of corticotropin-releasing factor actions in the brain: the role of the locus coeruleus.

Authors:  H Lehnert; C Schulz; K Dieterich
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

Review 10.  Synaptic physiology of central CRH system.

Authors:  Joel P Gallagher; Luis F Orozco-Cabal; Jie Liu; Patricia Shinnick-Gallagher
Journal:  Eur J Pharmacol       Date:  2008-02-01       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.